Research Nester released a report titled “Prostatic Arterial Embolization Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global prostatic arterial embolization market in terms of market segmentation by product, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Prostatic arterial embolization is a non-surgical procedure for the treatment of benign prostatic hyperplasia among men. It is an increasingly common prostate condition in which the gland swells up and blocks the urinary passage.

The market for prostatic arterial embolization is estimated to witness a significant CAGR during the forecast period, i.e., 2019-2027 which can be attributed to the rising demand for this procedure among the male population. The market is segmented by product, by end user and by region. On the basis of end user, the market is further segmented into hospitals, ambulatory surgical centers and clinics, out of which, the hospitals segment is estimated to hold the largest market share in prostatic arterial embolization market. This can be attributed to the increasing number of patients with prostatic hyperplasia in the hospitals. Data presented by the U.S. Centers for Disease Control and Prevention suggests that around 202,000 visits to hospital emergency departments were made by men above the age of 65 with urinary system symptoms in the U.S. during 2015. The increasing demand for treatment of prostate disorders in hospitals is estimated to positively impact the growth of the market during the forecast period.

Geographically, the market in Asia-Pacific region is anticipated to witness the significant growth rate in prostatic arterial embolization market on account of growing improvements in the medical industry along with increasing government initiatives for development of healthcare infrastructure in the region. The largest share in the prostatic arterial embolization market is estimated to be held by the market in North America region as a result of developed healthcare industry and rising demand for better treatment methods among the population.

Increasing Cases Of Prostate Hyperplasia To Support The Growth Of Prostatic Arterial Embolization Market

The growing number of patients with prostate hyperplasia is a major factor estimated to drive the market growth. Increasing awareness among people about the presence of new and improved medical treatments including prostatic arterial embolization is an additional factor anticipated to propel the market growth in upcoming years.

However, the ‘post prostatic arterial embolization (PAE) syndrome’ involving symptoms such as fever, nausea, frequent urination and pain is anticipated to restrict the growth of prostatic arterial embolization market during the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global prostatic arterial embolization market which includes company profiling of Merit Medical Systems (MMSI), Boston Scientific (BSX), Mentice (MN2), Siemens Healthineers (SHL), Terumo Europe NV and General Electric Company (GE). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global prostatic arterial embolization market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.